Pain management solution offered by Promex and Realeve honored by MedTech Breakthrough Awards
Revolutionary Pulsante Technology Transforms Chronic Pain Management
The world of neurostimulation technology is making significant strides in the treatment of central nervous system disorders, particularly in the management of chronic pain. One of the most promising advancements is the Pulsante system, developed by Realeve, a medical device company with a focus on micro-neurostimulation.
Dr. Peter Bonutti, the founder and CEO of Realeve, is a seasoned professional with over 30 years of experience and more than 500 patents under his belt. His latest project, Pulsante, is set to change the way we approach chronic pain and neurological disorders.
Pulsante offers a drug-free, safe, and effective treatment option for patients suffering from chronic migraine and neuropathic pain. It provides a more holistic approach to treatment, going beyond just pain management. The system has received FDA Breakthrough Device designation and is clinically proven in over 700 patients.
The Pulsante technology is the first externally powered implantable neuromodulation device system for treating central nervous system disorders. It features a minimally invasive, battery-free, wireless compact SPG microstimulation implant. The implant is powered by the Pulsante RC-200 handheld device, which has the potential to treat a range of brain-related conditions.
In studies of chronic cluster headaches, 75% of participants reported a significant reduction in headache frequency and intensity using the Pulsante system over a four-week period. This promising result underscores the potential of Pulsante to revolutionize the treatment of chronic pain conditions.
Moreover, the MedTech Breakthrough Awards program, an independent market intelligence organization, recognised Realeve's Pulsante as the 2025 Best New Pain Management Technology Solution. This accolade further validates the groundbreaking nature of the Pulsante technology.
Future iterations of the Pulsante technology may incorporate AI-based pain tracking and predictive analytics, offering even more precise treatment and improving patient outcomes. This advancement is expected to make the Pulsante system an alternative to traditional, more invasive therapies due to its compact and wearable nature, as stated by Dave Fromm, chief operations officer at Promex.
The field of neurostimulation technology is moving towards highly sophisticated, miniaturized, and power-efficient implantable microsystems capable of precise neural interfacing combined with effective peripheral and central neurostimulation methods. These advancements are significantly improving chronic pain management and CNS disorder therapies.
Neurostimulation has shown promise in treating not only chronic pain but also sleep disorders and anxiety. As such, the Pulsante technology's potential applications extend beyond chronic pain management, making it a promising solution for a variety of neurological conditions.
By reducing reliance on medications and offering patients greater independence, Pulsante improves quality of life and healthcare delivery. The future of neurostimulation technology is undeniably bright, and Pulsante is at the forefront of this exciting development.
[1] High-density neural interfacing microelectrode arrays enabling brain implants that record and stimulate neural activity with thousands of channels. [2] Advances in invasive and non-invasive neuromodulation (such as deep brain stimulation and transcranial stimulation) have led to more precise and personalized treatment modalities for neurological disorders, including chronic pain. [3] The overall nerve repair and regeneration market is experiencing rapid growth driven by breakthroughs in neurostimulation and biomaterial technologies, with digital neurostimulation devices like spinal cord and deep brain stimulators being increasingly used for chronic neurological conditions and pain control. [4] Progress in peripheral nerve stimulation (PNS) with micro-implantable pulse generators has shown efficacy in managing chronic pain conditions in large randomized controlled trials. These devices are small, targeted, and minimally invasive, representing a new generation of neurostimulation options for chronic pain alleviation. [5] Advances in both invasive and non-invasive neuromodulation (such as deep brain stimulation and transcranial stimulation) have led to more precise and personalized treatment modalities for neurological disorders, including chronic pain.
- The Pulsante technology, a revolutionary advancement in digital health, is transforming the management of chronic pain and other neurological disorders, such as migraines and neuropathic pain, by providing a safe, drug-free, and effective treatment option.
- The field of science has seen significant growth in the arena of neurostimulation technology, with promising applications extending beyond chronic pain management to sleep disorders, anxiety, and other mental-health conditions.
- The overall market for nerve repair and regeneration is rapidly expanding due to breakthroughs in neurostimulation and biomaterial technologies, with digital health solutions like Pulsante playing a key role in the treatment of chronic neurological conditions and pain control.
